Key Takeaways J&J's MedTech unit posted $8.43B in Q3 sales, up 5.6% on an operational basis.Cardiovascular growth from Abiomed and Shockwave drove stronger MedTech results.J&J plans to spin off its Orthopaedics arm to sharpen focus on faster-growing MedTech areas.Johnson & Johnson's (JNJ) medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J’s total revenues.In the third quarter, MedTech s ...